Optimizing β-Lactams against Tuberculosis

doi:10.1164/rccm.201911-2149LE

Return

Optimizing β-Lactams against Tuberculosis

2020-05-01

DOI：10.1164/rccm.201911-2149LE

Original

Save

View PDF

Abstract

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

American Journal of Respiratory and Critical Care Medicine

IF:

19.4

Papers:

1.8W

Citations:

6.7W

Organization

GlaxoSmithKline

Scholars:

1.8W

Papers: 9.6K

Citations: 39

stellenbosch university

Scholars:

1.4W

Papers: 1.2W

Citations: 17

Cited Papers

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-09-01

OAAI

van Rijn, Sander P.; Srivastava, Shashikant; Wessels, Mireille A.; van Soolingen, Dick; Alffenaar, Jan-Willem C.; Gumbo, Tawanda

Save

β-Lactams against Tuberculosis - New Trick for an Old Dog?

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2016-07-28

105

OAAI

Diacon, Andreas H.; van der Merwe, Lize; Barros-Aguirre, David

Save

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-05-01

OAAI

Zuur, M. A.; Ghimire, S.; Bolhuis, M. S.; Wessels, A. M. A.; van Altena, R.; de lange, W. C. M.; Kosterink, J. G. W.; Touw, D. J.; van der Werf, T. S.; Akkerman, O. W.; Alffenaar, J. W. C.

Save